News & Insights
Company updates, publications, and perspectives in precision oncology.
Latest updates
December 17, 2025
Antigenix Therapeutics Emerges from Stealth with $7 Million Seed Financing to Advance Development of Novel Antibody-Drug Conjugate Therapies
Antigenix Therapeutics is coming out of Stealth with $7 million in seed funding to advance the development of novel antibody-drug conjugate (ADC) therapies for cancers resistant to current treatments. With this funding, it will begin preparing its pre-clinical program based on a novel target platform, advancing toward IND submission and the development of its first investigational candidates.
